Your browser doesn't support javascript.
Prevalence of Anti-SARS-CoV-2 Antibodies in Poznan, Poland, after the First Wave of the COVID-19 Pandemic.
Lorent, Dagny; Nowak, Rafal; Roxo, Carolina; Lenartowicz, Elzbieta; Makarewicz, Aleksandra; Zaremba, Bartosz; Nowak, Szymon; Kuszel, Lukasz; Stefaniak, Jerzy; Kierzek, Ryszard; Zmora, Pawel.
  • Lorent D; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Nowak R; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Roxo C; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Lenartowicz E; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Makarewicz A; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Zaremba B; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Nowak S; Department and Clinic of Tropical and Parasitic Diseases, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
  • Kuszel L; Department of Medical Genetics, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
  • Stefaniak J; Department and Clinic of Tropical and Parasitic Diseases, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
  • Kierzek R; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
  • Zmora P; Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland.
Vaccines (Basel) ; 9(6)2021 May 21.
Article in English | MEDLINE | ID: covidwho-1305834
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
In comparison to other European countries, during the first months of the COVID-19 pandemic, Poland reported a relatively low number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. To estimate the scale of the pandemic in Poland, a serosurvey of antibodies against SARS-CoV-2 was performed after the first wave of COVID-19 in Europe (March-May 2020). Within this study, we collected samples from 28 July to 24 September 2020 and, based on the ELISA results, we found that 1.67% (25/1500, 95% CI 1.13-2.45) of the Poznan (Poland) metropolitan area's population had antibodies against SARS-CoV-2 after the first wave of COVID-19. However, the presence of anti-SARS-CoV-2 IgG antibodies was confirmed with immunoblotting in 56% (14/25) samples, which finally resulted in a decrease in seroprevalence, i.e., 0.93% (14/1500, 95% CI 0.56-1.56). The positive anti-SARS-CoV-2 IgG results were associated with age, occupation involving constant contact with people, travelling abroad, non-compliance with epidemiological recommendations and direct contact with the novel coronavirus. Our findings confirm the low SARS-CoV-2 incidence in Poland and imply that the population had little herd immunity heading into the second and third wave of the pandemic, and therefore, that herd immunity contributed little to preventing the high numbers of SARS-CoV-2 infections and COVID-19-related deaths in Poland during these subsequent waves.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9060541

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9060541